



ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF ACUTE PANCREATITIS

General Surgery

Dr. Rakess. P. S Postgraduate In Department Of General Surgery.

Dr. M. Senthilvelan Professor.

Dr. K. Balagurunathan Professor.

ABSTRACT

Aim: To study the effect of low molecular weight heparin in the treatment of acute pancreatitis. **Methodology:** Patients presenting to emergency room of Sri Lakshmi Narayana institute of medical sciences with features of acute pancreatitis with duration of 72 hours or less. **Result:** Total number of patients in the study was 100. Most common age group affected was 30-50 years of age. Out of 100; 86 were male patients and 14 were female patients. **Conclusion:** The low molecular weight heparin improves the micro circulations as a result of it relieves the abdominal pain, halt the progression of the disease, reduces the severity and complication, shortens the length of hospital stay and enhances the cure rate.

KEYWORDS

Acute, pancreatitis, low molecular weight heparin.

INTRODUCTION

Acute pancreatitis is a disease which has many etiologies. Each etiology seems to affect the pancreatic acinar cell in some way that results in premature activation and retention of potent proteolytic enzymes. In early stages of pancreatitis, macrophages, neutrophils, endothelial cells are activated. Preinflammatory cytokines are released and inflammation factors are elevated during acute pancreatitis and have been implicated in progression of pancreatitis associated microvascular disturbance and hemorrhagic necrosis.

Ischemia, reperfusion injury and tiny thrombosis are closely associated with pancreatic microcirculation disturbance (1). Severe acute pancreatitis [SAP] is severe and frequently a lethal disorder. Its mortality rate reaches up to 25 to 40% (2). SAP is usually complicated with systemic inflammatory cascades and microcirculatory disturbances-related morbidity due to infected prepancreatic necrosis.

Microcirculation disturbance is a trigger factor and plays an important role in the development of multiorgan failure (3, 4). Due to high mortality rate, search for newer modality of treatment is the hot point in the fields of pancreatic surgery. Low molecular weight heparin (LMWH) is known to possess a special anti-thrombin activity which is stronger and safer than unfractionated heparin. LMWH can reduce the release of cytokines and inflammatory mediators, resulting in an improvement of the microcirculation of pancreas. Our experimental study provides evidence that LMWH can block the initiation of an inflammatory storm, leading to improvement of microcirculation system; and has anti-thrombus effect to reduce the formation of microthrombosis in pancreas. These findings demonstrate the important therapeutic effect of LMWH in the treatment of acute pancreatitis.

MATERIALS AND METHODS

Study Area: Sri Lakshmi Narayana Institute of Medical Sciences

Study Population: Patients admitted in the surgery department with a diagnosis of acute pancreatitis of duration of 72 hours or less.

Inclusion Criteria:

Patients diagnosed with acute pancreatitis based on the following 2 criteria:

1. Abdominal pain characteristic of acute pancreatitis (duration < 72 hrs).
2. Serum amylase and/or lipase $\geq$ 3 times the upper limit of normal.

Exclusion Criteria:

1. The presence of chronic pancreatitis and gall stone induced pancreatitis
2. Hypersensitivity to the administration of low molecular weight heparin or radiocontrast agents
3. Computed tomography (CT) findings suggestive of complicated pancreatitis
4. Pregnant or breastfeeding

5. Coagulation disturbances
6. Severe comorbidities

Study Period: September 2022-August 2023

Sample Size: 100, All the patients eligible by inclusion criteria to be included in the study.

Study Design: An observational study to be conducted on patients admitted in surgery department for the above study.

Informed consent will be taken from each.

OBSERVATION AND ANALYSIS

Age Distribution

AGE DISTRIBUTION
TABLE-1

AGE (IN YRS)	NO OF PATIENTS	PERCENTAGE
< 30	24	24%
31-40	30	30%
41-50	29	29%
> 50	17	17%

Age In Years

TABLE-2

TREATMENT	AGE IN YEARS	
	MEAN	SD
WITH HEPARIN	40	9.44
WITHOUT HEPARIN	40.04	11.92
P VALUE - 0.985		
NON SIGNIFICANT		
UNPAIRED T TEST		

AGE DISTRIBUTION AMONG GROUPS

TABLE-3

AGE (IN YRS)	TREATMENT	
	WITH HEPARIN	WITHOUT HEPARIN
< 30	11	13
31-40	14	16
41-50	16	13
> 50	9	8
P VALUE - 0.880		
NON SIGNIFICANT		
KRUSKAL WALLIS TEST		

SEX DISTRIBUTION

TABLE-4

SEX	NO OF PATIENTS	PERCENTAGE
MALE	86	86%
FEMALE	14	14%

SEX DISTRIBUTION AMONG GROUPS

TABLE-5

SEX	TREATMENT	
	WITH HEPARIN	WITHOUT HEPARIN
MALE	44	42
FEMALE	6	8
P VALUE - 0.564		

FINAL OUTCOME

TABLE-6

FINAL OUTCOME	NO OF PATIENTS	PERCENTAGE
RECOVERED	96	96%
DIED	4	4%

FINAL OUTCOME AMONG GROUPS

TABLE-7

FINAL OUTCOME	TREATMENT	
	WITH HEPARIN	WITHOUT HEPARIN
RECOVERED	50	46
DIED	0	4
P VALUE - 0.041		
SIGNIFICANT		
CHI SQUARE TEST		

DISCUSSION:

Acute pancreatitis runs a severe course in a minority of patients. However, this subset is responsible for the burden of the disease. Therefore, decreasing the burden of acute pancreatitis can only be achieved with successful management strategies towards the condition. Previous clinical and experimental data revealed that acute pancreatitis fate was dictated in the early hours of pancreatitis, and microcirculation impairment was the pivotal derangement leading to necrosis and further damage. The presence of a hematocrit value of greater than 44 % and failing to decrease it with intravenous fluid boluses was considered to predict a severe prognosis. Hemoconcentration may cause microcirculation impairment and may play an essential role in the transition of edematous to necrotizing pancreatitis. The abundance of several inflammatory cytokines in the pancreas microenvironment in the setting of acute pancreatitis is also considered as one of the precipitating events. Pro-inflammatory cytokines, such as interleukins- IL-1 β , IL-6, and TNF- α increase during acute pancreatitis and are responsible for the progression of microvascular disturbance. The microcirculatory disruption is as essential as enzymatic and free radical damage in the pathogenesis of acute pancreatitis. Thrombosis, associated with denudation of endothelial cells, sludge formation, and resultant stasis, in the pancreatic circulation is an event occurring as early as mucoid swelling within the acini in the course of AP. These described changes in the pancreatic tissue usually start from the gland's peripheral part and extend toward the gland's center part. In addition to the microthrombi formation, there will be an accumulation of fibrin at the distal portion of the thrombus.

Enoxaparin is low molecular weight heparin that binds to antithrombin III and accelerates antithrombin III activity (A.T.I.I.I.). By activating antithrombin III, Enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa is involved in catalyzing prothrombin's conversion to thrombin and prevents the formation of fibrin clot. The heparin - antithrombin III complex reduces the activity of trypsin and chymotrypsin. It inhibits trypsinogen activation, thereby preventing the progression of the disease.

CONCLUSION:

Findings From Our Study Found that use of LMWH in treatment of Acute pancreatitis, which acts by improving microcirculation is an effective drug in the non-surgical treatment of acute pancreatitis. As per our study, the APACHE II Scores reduced considerably in the group treated with LMWH, suggesting that there was a considerable improvement in laboratory values, higher cure rate and lower complication. Such as Necrosis, Abscess, sepsis and Organ failure etc. Thus LMWH can effectively relieve acute pancreatitis related inflammation and reduce incidence of complications. LMWH can rapidly relieve abdominal pain, halt the progression of diseases, reduce the severity and complication, shorten the length of hospital stay and enhance the cure rate.

REFERENCES

- [1]. Qiu F, Lu XS, Huang YK. Effect of low molecular weight heparin on pancreatic microcirculation in severe acute pancreatitis in rodent model. *Chin Med J* 2007;120:2260-3.
- [2]. Renzulli, Jakob SM, Tauber M, Candinas D; case oriented discussion of interdisciplinary management pancreatology 2005;5:145-156
- [3]. Schneider C, Pietschmann M, Hartwig W, et al. Inosine reduces microcirculatory disturbance and inflammatory disturbance and inflammatory organ damage in experimental acute pancreatitis in rats. *Am J Surg* 2006;191:510-514
- [4]. Qiu F, Lu XS. Severe acute pancreatitis and multiple organ dysfunction syndrome. *Foreign Med Sci (pathophysiol Clin Med)* (Chin) 2004; 6:85-88
- [5]. Xin-Sheng L, Fu Q, Jie-Qin L, Qin-Qiao F, Ri-Guang Z, Yu-Hang A et al. Low Molecular Weight Heparin in the Treatment of Severe Acute Pancreatitis: A Multiple Centre Prospective Clinical Study. *Asian Journal of Surgery*. 2009;32(2):89-94.
- [6]. Ai-Hua Han¹*, Guo-Qing Yu¹ and Hua-Zhen Yin². Clinical effects of low-molecular-weight heparin combined with ulinastatin in children with acute pancreatitis. *Tropical Journal of Pharmaceutical Research* August 2016; 15 (8): 1787-1792
- [7]. Jun-Dong Du¹*, Xi Zheng²*, Zhi-Qiang Huang³, Shou-Wang Cai¹, Jing-Wang Tan¹, Zhan-Liang Li¹, Yong-Ming Yao¹, Hua-Bo Jiao¹, Hui-Nan Yin¹ And Zi-Man Zhu¹. Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis. *Exp Ther Med*. 2014 Jul; 8(1): 141-146.
- [8]. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. *Arch Surg* 1993; 128:586.
- [9]. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut* 2008;57(12):1698-703. Epub 2008/06/04.
- [10]. talukdar R, Clemens M, Vege SS. Moderately Severe Acute Pancreatitis; Prospective Validation of this New Subgroup of Acute Pancreatitis. *Pancreas*. 2011. Epub 2011/10/22.